|19.46||-0.3700||-1.87%||Vol 274.62K||1Y Perf -16.72%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||-0.37 -1.90%|
|Target Price||47.40||Analyst Rating||Strong Buy 1.00|
|Potential %||143.58||Finscreener Ranking||★★★★★ 60.31|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★★★ 57.06|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★★ 58.48|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||50.17||Earnings Rating||—|
|Market Cap||523.68M||Earnings Date||2nd Nov 2023|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.92|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||220.70K|
|Avg. Monthly Volume||209.43K|
|Avg. Quarterly Volume||232.27K|
Castle Biosciences Inc. (NASDAQ: CSTL) stock closed at 19.46 per share at the end of the most recent trading day (a -1.87% change compared to the prior day closing price) with a volume of 274.62K shares and market capitalization of 523.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 135 people. Castle Biosciences Inc. CEO is Derek J. Maetzold.
The one-year performance of Castle Biosciences Inc. stock is -16.72%, while year-to-date (YTD) performance is -17.33%. CSTL stock has a five-year performance of %. Its 52-week range is between 9.2601 and 29.59, which gives CSTL stock a 52-week price range ratio of 50.17%
Castle Biosciences Inc. currently has a PE ratio of -11.10, a price-to-book (PB) ratio of 1.46, a price-to-sale (PS) ratio of 6.24, a price to cashflow ratio of 230.60, a PEG ratio of -, a ROA of -11.88%, a ROC of -12.79% and a ROE of -12.87%. The company’s profit margin is -47.13%, its EBITDA margin is -43.90%, and its revenue ttm is $98.70 Million , which makes it $3.75 revenue per share.
Of the last four earnings reports from Castle Biosciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.92 for the next earnings report. Castle Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Castle Biosciences Inc. is Strong Buy (1), with a target price of $47.4, which is +143.58% compared to the current price. The earnings rating for Castle Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Castle Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Castle Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.41, ATR14 : 0.82, CCI20 : 39.08, Chaikin Money Flow : 0.10, MACD : 0.98, Money Flow Index : 44.90, ROC : -0.92, RSI : 61.18, STOCH (14,3) : 41.01, STOCH RSI : 0.00, UO : 52.72, Williams %R : -58.99), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Castle Biosciences Inc. in the last 12-months were: Bradbury Daniel (Sold 16 460 shares of value $329 857 ), Cole G. Bradley (Option Excercise at a value of $0), Daniel M. Bradbury (Sold 49 974 shares of value $1 151 998 ), Derek J. Maetzold (Option Excercise at a value of $0), Derek J. Maetzold (Sold 36 600 shares of value $852 883 ), Frank Stokes (Option Excercise at a value of $13 520), Goldberg Ellen (Buy at a value of $138 008), Goldberg Ellen (Option Excercise at a value of $0), Harrison Miles (Option Excercise at a value of $0), Juvenal Tobin (Sold 0 shares of value $-14 753 ), Kim Caple (Option Excercise at a value of $0), Kristen Oelschlager (Option Excercise at a value of $17 155), Maetzold Derek (Sold 64 151 shares of value $1 457 820 ), Olson Tiffany (Option Excercise at a value of $0), Tobin W. Juvenal (Option Excercise at a value of $0)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.